Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(117 productos)
- EGFR(562 productos)
- FAK(72 productos)
- FLT(89 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(177 productos)
- JAK(245 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(52 productos)
- VDA(2 productos)
- VEGFR(239 productos)
Mostrar 6 subcategorías más
Se han encontrado 2243 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
F-1
CAS:F-1: Potent ALK/ROS1 inhibitor with 2.1-3.9 nM IC50s; suppresses p-ALK signaling.Fórmula:C22H27ClN8O3SPureza:97.66%Forma y color:SolidPeso molecular:519.02Ref: TM-T11254
1mg73,00€5mg140,00€10mg188,00€25mg316,00€50mg447,00€100mg620,00€200mg843,00€1mL*10mM (DMSO)168,00€Lidocaine Hydrochloride hydrate
CAS:Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property.Fórmula:C14H22N2O·HCl·H2OPureza:99.95%Forma y color:SolidPeso molecular:288.82JAK-IN-15
CAS:JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).Fórmula:C22H23FN4O3SForma y color:SolidPeso molecular:442.51ALK-IN-13
CAS:ALK-IN-13 is an ALK inhibitor.
Fórmula:C29H39ClN7O2PForma y color:SolidPeso molecular:584.1Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.772-Keto Crizotinib
CAS:2-Keto Crizotinib is an active lactam metabolite of crizotinib.Fórmula:C21H20Cl2FN5O2Pureza:98%Forma y color:SolidPeso molecular:464.32Verucopeptin
CAS:Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.Fórmula:C43H73N7O13Forma y color:SolidPeso molecular:896.08PACAP-38 (31-38), human, mouse, rat TFA
PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.Fórmula:C49H84F3N17O13Pureza:98%Forma y color:SolidPeso molecular:1176.29PROTAC EGFR degrader 6
CAS:PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.Fórmula:C49H57FN12O5Forma y color:SolidPeso molecular:913.05EGFR-IN-144
EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.
Fórmula:C20H17Cl2N3O3Forma y color:SolidPeso molecular:418.273TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Forma y color:Odour SolidSNIPER(ABL)-015
SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5Fórmula:C58H70F3N9O9Pureza:98%Forma y color:SolidPeso molecular:1094.23E7090
CAS:E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.Fórmula:C32H37N5O6Forma y color:SolidPeso molecular:587.67VEGFR2/HDAC1-IN-1
VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.Pureza:98%Forma y color:Odour SolidBTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Forma y color:Odour SolidHG-7-85-01
CAS:HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.
Fórmula:C31H31F3N6O2SPureza:98.08%Forma y color:SolidPeso molecular:608.68PF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Fórmula:C46H50F3N13O8Pureza:98%Forma y color:SolidPeso molecular:969.97VEGFR-2-IN-64
VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.Fórmula:C72H123N9O6Forma y color:SolidPeso molecular:1210.8PROTAC EGFR degrader 2
Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.Fórmula:C58H72ClFN12O8SForma y color:SolidPeso molecular:1151.78Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Fórmula:C36H35FN6O10Forma y color:SolidPeso molecular:730.696
